Singleron Biotechnologies, a leader in single cell multi-omic solutions for precision medicine, announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length Transcriptome Library Kit.
AccuraSCOPE Single Cell Transcriptome and Genome Library Kit opens new possibilities for single cell multi-omic analysis by profiling the entire genome and transcriptome simultaneously. In addition to single cell RNA sequencing, this method enables deep single cell genome sequencing, amplifying ultra-low quantities of DNA from individual cells. This facilitates the comprehensive detection of single nucleotide variants and chromosomal aberrations at single cell level. Using proprietary bead-based technology, it captures both genomic DNA and mRNA from each cell and converts them to high-quality sequencing libraries. The integrated analysis of a cell’s transcriptome and genome provides a comprehensive understanding of cellular heterogeneity in normal development and disease. The kit’s multiplex design and streamlined workflow allow for single-cell mRNA and DNA library preparation from up to 384 single cells in parallel in a single day, significantly reducing time and costs.
Another new product in the AccuraSCOPE portfolio, AccuraSCOPE Single Cell Full-Length Transcriptome Library Kit, adds full-length, comprehensive, and rapid RNA sequencing library preparation to the toolkit. It enables the detection of alternative splicing at the single cell level, substantially reducing hands-on time compared to existing full-length single cell RNAseq methods.
The latest innovations were developed to particularly aid clinical researchers in oncology, gene, and cell therapy, as well as immunology and reproductive biology. Accurate detection of genomic and transcriptomic changes can unveil the relationship between genomic dynamics and gene expression profiles as well as uncover the functional impact of point mutations and copy number variations.
To meet customers’ data analysis needs when using the new AccuraSCOPE products, Singleron has developed two bioinformatic analysis pipelines. The RNA sequencing data analysis pipeline covers the analysis workflow from FASTQ files to count matrix, while the DNA data analysis pipeline starts with FASTQ files and includes variance calling and variant annotation.
Both kits are compatible with well-based automation workstation, flow cytometry cell sorting, or micropipette aspiration.
Singleron biotechnologies advances precision medicine and human health through pioneering single cell multi-omics solutions. Its current product portfolio includes high throughput instruments for automated single cell processing and tissue dissociation, reagents, bioinformatics software, and a comprehensive single cell knowledgebase.
Founded in 2018, Singleron operates globally with offices, laboratories, and manufacturing facilities in Germany, Singapore, China, and the US. Its products are used in over 3000 laboratories in hospitals, research institutes, and pharmaceutical companies in more than 20 countries.
Check out our mRNA service to expedite your vaccine research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha 293 cell AAV high-yield platform and the π-Omega plasmid high-yield platform. PackGene's mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Rare diseases currently afflict 300 million people worldwide and 30 million people in the U.S. alone. However, 95% of these diseases lacked an FDA-approved treatment as of January 2023. One reason, industry leaders say, is cost. A 2019 study estimated that orphan drug...
SN Bioscience's pioneering nanoparticle anticancer drug, SNB-101, has sparked hope for patients battling various forms of cancer. Developed from the highly insoluble SN-38 into polymer nanoparticles, SNB-101 has exhibited significant improvements in efficacy and...
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
- Conducted in Collaboration with Columbia University, the CheMo4METPANC Phase 2 trial is the first large, multi-center, randomized study evaluating motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies compared to chemo alone - - Gulam Manji, MD,...
The success of mRNA vaccines against COVID-19 has unleashed a flood of interest in using the technology to create more vaccines and treatments for everything from rare diseases and infections to cancer. But before new mRNA therapeutics are put to use, they need to be...